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Locally advanced breast cancer (LABC) is associated with dire prognosis despite progress in multimodal treatments. We evaluated
several clinical and pathological features of patients with either noninflammatory (NIBC, cT4a-c) or inflammatory (IBC, cT4d) breast
cancer to identify subset groups of patients with high risk of early treatment failure. Clinical and pathological features of 248 patients
with LABC, who were treated with multimodality treatments including neoadjuvant chemotherapy followed by radical surgery and
radiotherapy were reassessed. Tumour samples obtained at surgery were evaluated using standard immunohistochemical methods.
Overall, 141 patients (57%) presented with NIBC (cT4a-c, N0-2, M0) and 107 patients (43%) with IBC (cT4d, N0-2, M0). Median
follow-up time was 27.5 months (range: 1.6–87.8). No significant difference in terms of recurrence-free survival (RFS) (P¼0.72),
disease-free survival (DFS) (P¼0.98) and overall survival (OS) (P¼0.35) was observed between NIBC and IBC. At the multivariate
analysis, patients with ER- and PgR-negative diseases had a significantly worse RFS than patients with ER- and/or PgR-positive diseases
(hazard ratio: 2.47, 95% CI: 1.33–4.59 for overall). The worst RFS was observed for the subgroup of patients with endocrine
nonresponsive and HER2-negative breast cancer (2-year RFS: 57% in NIBC and 57% in IBC) A high Ki-67 labelling index (420% of
the invasive tumour cells) and the presence of peritumoral vascular invasion (PVI) significantly correlated with poorer RFS in overall
(HR 2.69, 95% CI: 1.61–4.50 for Ki-67420% and HR 2.27, 95% CI: 1.42–3.62 for PVI). Patients with endocrine nonresponsive LABC
had the most dire treatment outcome. High degree of Ki-67 staining and presence of PVI were also indicators of higher risk of early
relapse. These factors should be considered in therapeutic algorithms for LABC.
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Locally advanced breast cancer (LABC) is a heterogeneous group
of diseases. It include tumours with locoregional lymph node
metastases, primary breast carcinomas infiltrating skin or chest
wall (cT4 a-c), as well as inflammatory breast carcinoma (cT4d,
IBC), the latter commonly considered as a distinct clinicopatho-
logical entity (Singletary et al, 2002). The American Joint
Committee on Cancer (AJCC) based the IBC diagnosis on the first
clinicopathological description by Haagensen (1971). Typically, the
clinical presentation of IBC includes tenderness, induration,
warmth, peau d’orange, often without an underlying palpable
mass; these signs progress quite rapidly (Greene et al, 2002;
Anderson et al, 2003). Several retrospective studies that compared
patients with primary IBC and those with noninflammatory breast
cancer (NIBC) led to the notion that IBC is clinically and
biologically more aggressive (Low et al, 2004; Cristofanilli et al,
2007). Inflammatory breast cancer more frequently than NIBC is
characterised by an early age at diagnosis, negative hormone
receptor status, high nuclear grade, HER2/neu gene amplification
and overexpression, and by pronounced neo-angiogenic and
invasive features (Turpin et al, 2002; Anderson et al, 2003; Sawaki
et al, 2006).
In contrast, controversies exist on the prognostic value of the T4
category for NIBC according to the TNM classification. Indeed,
several authors suggested that NIBC currently classified as T4a–c
should be classified according to tumour size, because the size of
the primary tumour or the nodal involvement, rather than direct
invasion of the chest wall or ulceration of the skin, might better
indicate prognosis (Gueth et al, 2007).
Limited information on prognostic and predictive parameters
for both IBC and NIBC is currently available, and it is largely
derived from old retrospective series, collected during several
years. In fact, despite possible differences in the clinical and
biological behaviour of a T4 presentation, either inflammatory or
not, patients with either presentation are commonly treated with
similar combined-modality regimens.
To seek information on the prognostic value of clinical and
pathological features of both IBC and NIBC collected at surgery
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sand to identify a subset of patients with very high risk of early
relapse, we evaluated the treatment outcome in 248 patients with
LABC (cT4a–d) who were operated at the European Institute of
Oncology (EIO) between 1999 and 2006.
PATIENTS AND METHODS
Patients
Prospectively collected data from consecutive patients with
histologically and/or cytologically proven clinical (c) stage T4a–d,
N0-2 and submitted to surgery at the IEO from November 1999 to
November 2006 were analysed. Clinical diagnosis of T4 was
performed by the surgeon who asked an oncologist consult for the
patients to start neoadjuvant treatment. In agreement with T4d
classification in the AJCC system, clinical diagnosis of IBC required
presence of erythema, heat, ridging or peau d’orange on breast. Data
on the patient’s medical history, concurrent diseases, type of surgery,
histopathological features and results of staging procedures (blood
chemistry, haematological values, bone scan, chest film and upper
abdominal ultrasound examination) were reviewed.
Treatment
Patients were treated under best-known multidisciplinary
management. All patients received preoperative chemotherapy
(plus/minus endocrine therapy) and adequate local treatment. In
all, 106 patients with IBC underwent a modified radical
mastectomy followed by external beam radiotherapy. Owing to
the presence of skin involvement at the onset of diagnosis, an
extensive skin removal was performed and in selected cases a
musculocutaneous flap was needed for surgical closure. Immediate
breast reconstruction using an expander or a prothesis was not
used because of the need for postoperative locoregional radio-
therapy. Postoperative irradiation was proposed to all patients.
The selection of adjuvant systemic treatment was based upon
indicators of responsiveness to treatment (endocrine responsive-
ness of the tumour) and evaluation of risk. For patients with
endocrine responsive disease, adjuvant endocrine therapy alone
according to menopausal status was prescribed (tamoxifen or
aromatase inhibitor) for a duration of 5 years in postmenopausal
patients and the combination of tamoxifen for 5 years plus
gonadotropin releasing hormone analogues for at least 2 years in
premenopausal patients (Goldhirsch et al, 1998). In patients at
higher risk (e.g., pN1a disease) and/or features of limited
endocrine responsiveness, chemotherapy was added to the
endocrine treatment programme.
Response criteria
Responses to neoadjuvant chemotherapy were evaluated according
to both radiological (breast ultrasound plus Rx mammography)
and clinical evaluation and graded according to standard WHO
criteria. Pathological complete remissions (pCRs) were evaluated
according to the criteria by Kuerer et al (1999). In particular, the
absence of invasive cancer on both the primary breast tumour and
axillary lymph nodes qualified for pCR.
Pathology and immunohistochemistry
This is a single institution study. All patients had pathological
evaluation performed during final surgery at the EIO. Surgical
specimens were extensively sampled for the evaluation of residual
tumour after primary chemotherapy. In case of lack of gross
evidence of tumour, the quadrantectomy specimens were entirely
blocked in paraffin and examined histologically, as were the
tumour-bearing quadrants of the mastectomies. In the latter cases,
the other quadrants were also thoroughly evaluated with the
examination of at least three tissue blocks.
Immunostaining experiments for the localisation of ER and PgR,
HER2 protein and Ki-67 antigen were performed on consecutive
tissue sections from the residual tumour after surgery, as
previously reported (Colleoni et al, 1999). The following primary
antibodies were used: the monoclonal antibody (MAb) to ER
(Dako, Glostrup, Denmark; at 1/100 dilution), the MAb to PgR
(Dako; 1/800), the MIB-1 MAb to the Ki-67 antigen (Immunotech,
Marseille, France; 1/1200) and the polyclonal antiserum (Dako;
1/3200) to the HER2 protein.
Only nuclear reactivity was taken into account for ER, PgR and
Ki-67 antigen, whereas only an intense and complete membrane
staining in 410% of the tumour cells qualified for HER2
overexpression (3þ). The results were recorded as the percentage
of immunoreactive cells over at least 2000 neoplastic cells. The
value of 20% for Ki-67 labelling index (LI) was used as a cutoff in
distinguishing tumours with low (o20%) and high (X20%)
proliferative fraction (Colleoni et al, 1999). Steroid hormone
receptors status was classified as negative (lack of any ER and PgR
immunoreactivity, or o1% immunoreactive tumour cells), low
(ER and/or PgR o10% immunoreactive tumour cells) or positive
(ER and/or PgR X1% of the cells).
Statistical analysis
Characteristics of the two disease groups (NIBC and IBC) were
compared using Pearson’s w
2 test. The primary end point was
recurrence-free survival (RFS). Recurrence-free survival was
measured from the date of surgery to any locoregional invasive
recurrence (including ipsilateral breast recurrence), distant
recurrence, death for breast cancer or date of last follow-up visit,
whichever occurred first. Patients who died for nonbreast cancer
cause or patients who experienced a second primary cancer
(including contralateral breast cancer) were considered censored
at their event date. Second end points were disease-free survival
(DFS) and overall survival (OS). Disease-free survival was defined
as the length of time from the date of surgery to any relapse
(including ipsilateral breast recurrence), the appearance of a
second primary cancer (including contralateral breast cancer),
death or the date of last follow-up visit, whichever occurred first.
Overall survival was determined as the time from surgery until the
date of death (from any cause) or the date of last contact. The
median time of follow-up was calculated as both the median
observation time among all patients and the median observation
time among patients still alive at their last follow-up. Plots of the
survival curves were drawn using the Kaplan–Meier method. The
log-rank test was used to assess the survival difference between the
two disease groups and, separately for each group, between patient
and tumour characteristics at surgery. Patients achieving a
complete pathological response were excluded in the analyses
evaluating histopathological characteristics of the tumour assessed
at surgery (two patients in NIBC and five patients in IBC). Cox’s
proportional hazard regression models were used to assess the
prognostic significance of clinical and histopathological character-
istics of the tumour on RFS and to estimate the association
between disease group and RFS, after statistical adjustment for
patient and disease characteristics.
The model included year of surgery, age at surgery, number of
positive lymph nodes, hormone receptor status, HER2 over-
expression, Ki-67 LI, peritumoral vascular invasion (PVI) and
pathological response. In the univariate analysis, the Wald test was
used to evaluate significance of individual coefficients, and the
likelihood ratio test was used to assess factor with more than two
levels (e.g., lymph node involvement). Factors that were significant
at a P-value of 0.10 or less were entered into the multiple
regression model. Results from Cox’s models were expressed as
hazard ratios (HRs) with 95% confidence intervals (CIs). All
Locally advanced breast cancer and outcome
E Montagna et al
1746
British Journal of Cancer (2008) 98(11), 1745–1752 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sanalyses were performed with the SAS software version 8.02 (SAS,
Cary, NC, USA). All P-values were two sided.
RESULTS
Results
Overall, 504 patients were identified with a cT4 disease and were
available for the analysis. Patients who presented with recurrent
tumours (n¼19), metastatic disease at presentation (n¼99), other
previous tumour (n¼18), no primary chemotherapy (n¼84) and
male breast cancer (n¼5) were excluded. Finally, we removed
patients with LABC who received trastuzumab therapy
(31 patients), and the current analysis was restricted to 248
patients.
Patients’ characteristics are shown in Table 1. Tumours were
classified as IBC for 107 patients (43%) and as NIBC for 141 (57%).
There were no significant differences between the characteristics of
the two groups, except for the increased frequency of IBC in recent
years. As expected, the prevalent tumour histotype in both groups
was invasive ductal carcinoma, NOS (not otherwise specified). At
final surgery, the majority of patients presented with 44 positive
axillary nodes (70.7% in NIBC and 72.2% in IBC). An elevated
percentage of staining for Ki-67 was observed in 64 patients
(48.9%) with NIBC and in 56 patients (57.7%) with IBC. HER2 was
overexpressed in 25.4 and 22.5% of NIBC and IBC, respectively.
Treatment
Primary treatments are detailed in Table 2. All patients received
primary chemotherapy: infusional regimens were administered to
54 patients with NIBC and to 61 patients with IBC. A total of 35.4
and 22.4% of patients with NIBC and IBC received a taxane and
anthracycline-containing chemotherapy. A total of 52.5 and 72.0%
of patients with NIBC and IBC, respectively, received an
anthracycline combination chemotherapy. One hundred and
twenty-eight (90.8%) patients with NIBC and 106 (99.1%) patients
with IBC had a total mastectomy as the surgical treatment.
Thirteen patients with NIBC (9.2%) underwent quadrantectomy
with axillary dissection followed by external beam radiotherapy.
Adjuvant radiotherapy was performed in a similar proportion of
patients of the two cohorts: NIBC (94.3%), IBC (94.4%). Adjuvant
chemotherapy (with or without addition of endocrine therapy) was
prescribed to 81 (57.4%) and 57 (53.3%) patients with NIBC and
IBC, respectively. There was no significant difference in terms of
response to preoperative chemotherapy between the two groups
(partial response: 56.7% for NIBC and 57.9% for IBC).
Events
By 23 October 2007, the median follow-up among all patients was
27.5 months (range: 1.6–87.8), and median follow-up among
patients still alive at their last follow-up was 31.0 months (range:
2.0–87.8). A total of 25 out of 248 patients were lost to follow-up.
The Kaplan–Meier curves for OS, DFS and RFS are displayed in
Figure 1A–C. The estimated proportion of surviving patients at 2
and 5 years was 86% (95% CI: 79–93%) and 66% (95% CI: 56–77%)
for patients with NIBC and 88% (95% CI: 81–95%) and 73% (95%
CI: 56–90%) for IBC patients.
Recurrence-free survival at 2 years was 57% (95% CI: 47–66%)
and 57% (95% CI: 46–68%) for NIBC and IBC. No significant
difference in terms of RFS (P¼0.72), DFS (P¼0.98) and OS
(P¼0.35) was observed between the two groups.
Table 1 Patient and disease characteristics at surgery
NIBC,
N (% collected)
IBC,
N (% collected) P
a
Total no. 141 107
Year of surgery
1999–2001 65 (46.1) 16 (14.9)
2002–2003 35 (24.8) 35 (32.7) o0.001
2004–2006 41 (29.1) 56 (52.3)
Age (years)
o35 5 (3.5) 4 (3.7)
35–49 53 ()37.6 34 (31.8)
50–59 58 (41.1) 34 (31.8) 0.07
60–69 19 (13.5) 30 (28.0)
70+ 6 (4.3) 5 (4.7)
Histologic type
IDC 126 (90.6) 88 (86.3)
ILC 6 (4.3) 5 (4.9) 0.44
Others 7 (5.1) 9 (8.8)
NA 2 5
Lymph node involvement
None 11 (7.9) 12 (11.2)
1–3 30 (21.4) 18 (16.8) 0.51
4+ 99 (70.7) 77 (72.0)
Unknown 1 —
Ki-67
o20% 67 (51.1) 41 (42.3) 0.22
X20% 64 (48.9) 56 (57.7)
NA 2 5
Unknown 8 5
ER/PgR status
Positive
b 39 (28.7) 17 (17.0)
Low
c 52 (38.2) 40 (40.0) 0.08
Negative 45 (33.1) 43 (43.0)
NA 2 5
Unknown 3 2
HER2 status
Overexpressed 35 (25.4) 23 (22.5)
Not overexpressed 103 (74.6) 79 (77.5) 0.65
NA 2 5
Unknown 1 —
Peritumoral vascular invasion
Absent 70 (50.4) 42 (41.2)
Present 69 (49.6) 60 (58.8) 0.30
NA 2 5
ER¼oestrogen receptors; IBC¼inflammatory breast cancer; IDC¼invasive ductal
carcinoma; ILC¼invasive lobular carcinoma; NA¼not available in patients with
pathological complete response; NIBC¼noninflammatory breast cancer; PgR¼
progesterone receptors.
aUnknowns and NA were excluded.
bBoth ER and PgR
X10%.
cER or PgR between 1 and 9%.
Table 2 Primary treatment characteristics
NIBC,
N (% collected)
IBC,
N (% collected) P
Regimen
Anthracyclines 74 (52.5) 77 (72.0)
Anthracyclines and taxanes 50 (35.4) 24 (22.4)
Others 17 (12.1) 6 (5.6) 0.007
Infusional
a
Infusional therapy 54 (38.3) 61 (57.0)
No infusional therapy 87 (61.7) 46 (43.0) 0.005
IBC¼inflammatory breast cancer; NIBC¼noninflammatory breast cancer.
aRegimen
including continuous infusional fluorouracil.
Locally advanced breast cancer and outcome
E Montagna et al
1747
British Journal of Cancer (2008) 98(11), 1745–1752 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sHigh degree of immunostaining for Ki-67 correlated with worse
RFS in NIBC (Po0.0001) and in IBC (P¼0.0029) at the univariate
analysis as displayed in Figure 2A. Presence of PVI was associated
with poor RFS in NIBC (P¼0.18) and IBC (P¼0.01) as shown in
Figure 2B.
An exploratory analysis showed worse RFS for subgroup of
patients with basal-like (HER2 negative and ER negative)
compared with luminal (ER positive and HER negative) and
HER2-positive breast cancer. Recurrence-free survival at 2 years
for ER- and HER2-negative breast cancer was 39.2% in the NIBC
group and 40.5% in IBC patients as displayed in Figure 2C.
Multivariate analysis
Independent association between biological features and prob-
ability of relapse was analysed, and the results are displayed in
Tables 1–3.
Patients with ER- and PgR-negative disease had a significantly
shorter RFS than patients with ER- and/or PgR-positive disease
(HR 2.47, 95% CI: 1.33–4.59, P¼o0.001). A high proportion of
Ki-67 cell staining and presence of PVI significantly correlated
with poorer RFS (HR 2.69, 95% CI: 1.61–4.50, P¼o0.001 for
Ki-67420% and HR 2.27, 95% CI: 1.42–3.62, P¼o0.001 for PVI).
The lymph nodes involvement, years of surgery, age of patients,
HER2 status, neoadjuvant response and chemotherapeutic regimen
did not correlate at multivariate analysis with poorer RFS. When
we included in the analysis patients who received trastuzumab
therapy, HER2 status also did not correlate with worse RFS.
DISCUSSION
One of the most important factors predicting the risk of relapse in
patients with LABC after radical surgery is the type of presentation.
In particular, as recently reported on a large retrospective series,
the inflammatory presentation was associated with significantly
worse RFS and OS when compared with a noninflammatory locally
advanced disease (NIBC) (Cristofanilli et al, 2007). Unfortunately,
a limited number of prognostic and predictive factors were looked
at within the subgroups with either inflammatory (IBC) or NIBC.
These included number of involved lymph node (Klauber-DeMore
et al, 2006), tumour size (Carter et al, 1989), hormone receptor
status (Huang et al, 2005) and indicators of tumour proliferation
(Aas et al, 2003).
Current knowledge on these prognostic factors is largely
dependent upon older retrospective series. Surgical and staging
procedures, neoadjuvant and adjuvant treatments developed to
reduce the risk of relapse and mortality underwent substantial
changes, leading to a need to re-examine the relevance of new
findings from recently treated patients.
We analysed the pathological information obtained at surgery
and not at time of diagnosis, so we excluded patients who achieved
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Figure 1 (A) Overall survival, (B) DFS and (C) RFS in IBC and NIBC.
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spCR and those who were not amenable to surgery. However,
through the analyses of the histopathological features at final
surgery, we aimed to identify a subset of patients with high risk of
early treatment failure. This study provides insight to treatments
and prognoses of patients with LABC, because it is based on a
relatively large population of patients and on data collected in a
relatively short period of time, thus allowing consideration of
modern treatment procedures. The pathologists, surgeons and
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Figure 2 Recurrence-free survival, stratified by (A) Ki-67, (B) PVI and (C) ER/HER2 status in NIBC and IBC.
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reference. The results provide substantial additional evidence to
support the hypothesis that steroid hormone receptor status
defines distinct biological entities requiring a differentiated
approach to treatment and clinical trial investigation in LABC.
Limited data are available on the relationship between number of
cells expressing hormone receptors and outcome in large operable
tumours. This might be explained by the heterogeneity of the
assays and especially of cutoffs used in the various studies and by
the fact that initial biopsy upon which diagnosis and biological
characteristics were define was small in size not allowing the full
confidence in declaring the findings as representative for the entire
neoplasia. A potential role for steroid hormone receptors in
defining prognosis and responsiveness to cytotoxic treatment has
been reported (Lippman and Allegra, 1980; Colleoni et al, 2001,
2004; Kaufmann et al, 2007; Torrisi et al, 2007). In most of the
trials mentioned above, however, analyses were commonly
performed based on a so-called ‘receptor-negative grouping’,
which combines receptor-negative disease with those expressing
low receptor levels. In the present study, we demonstrated a higher
risk of early relapse for endocrine nonresponsive disease (defined
as having no steroid hormone receptor staining at all). In
particular, the results of the present study indicate that RFS at 2
years after primary therapy and surgery is significantly worse in
the cohort of patients with ER- and PgR-negative tumours
compared with ER-positive breast cancer, either in the NIBC or
in IBC group.
Retrospective studies that compared outcome of patients with
locally advanced breast of inflammatory and noninflammatory
types suggested that IBC is clearly associated with a worse
prognosis. In particular, the large experience on factors predicting
outcome in LABC was recently published by investigators from the
MD Anderson Cancer Center (MDACC; Cristofanilli et al, 2007).
Patients with IBC had decreased RFS compared with NIBC
tumours (5-year RFS, 33.1 vs 44.7%, P¼0.03) and worse OS
(5-year OS, 38.5 vs 52.1%, Po0.01), respectively. Looking at the
two cohorts without focusing on endocrine responsiveness, we did
not observe a significant difference in RFS (P¼0.72), DFS
(P¼0.98) and OS (P¼0.35) between patients with IBC and cT4
NIBC. In particular, DFS at 2 years was 57 and 57%, respectively,
for the two cohorts of patients.
As shown in Table 1, about 60% of the patients had endocrine
responsive disease. In these patients, a moderate but continuous
increased risk of relapse persisting over time can be hypothesised
indicating a need to reanalyse the data after a prolonged
follow-up.
Ki-67 is an antigen present in all phases of the cell cycle except
G0 (Greene et al, 2002). It is a measure of tumour proliferation that
has been correlated with outcome in several studies (Sahin et al,
1991; Domagala et al, 1996; Pietila ¨inen et al, 1996; Clahsen et al,
1999; Mandard et al, 2000). It has also been suggested that high
Ki-67 LI may be predictive of responsiveness to neoadjuvant
chemotherapy (Jansen et al, 1998; Chang et al, 2000; Archer et al,
2003; Trihia et al, 2003). The results of the present study indicate
that measures of tumour cell proliferation could potentially
identify patients who might require further therapy (adjuvant
chemotherapy as well as endocrine therapy) after surgery in LABC.
In fact, we observed worse RFS in patients with higher staining for
Ki-67 compared with a lower degree of staining. However, Ki-67
expression was measured at time of surgery (i.e., after neoadjuvant
chemotherapy) and the value at time of diagnosis is not available
for all patients. So, we did not analyse the potential role of
modification of Ki-67 expression before, during and after
neoadjuvant chemotherapy (Bottini et al, 2001; Burcombe et al,
Table 3 Univariate and multivariate Cox’s models for recurrence-free survival
Univariate HR (95% CI) P Multivariate HR (95% CI)
a P
cT
4d (IBC) vs 4a–c (NIBC) 1.08 (0.72–1.62) 0.72 0.73 (0.46–1.15) 0.17
Year of surgery
2003–2006 vs 1999–2002 0.96 (0.74–1.24) 0.77 — —
Age
X50 vs o50 0.91 (0.61–1.36) 0.64 — —
Lymph node involvement
1–3 vs noneo4 1.26 (0.46–3.44) —
X4 vs noneo4 1.58 (0.64–3.90) 0.45 — —
ER/PgR status
Low vs positive 1.00 (0.54–1.83) 1.12 (0.59–2.13)
Negative vs positive 2.49 (1.42–4.35) o0.001 2.47 (1.33–4.59) o0.001
HER2 status
Overexpressed vs not overexpressed 1.30 (0.84–2.02) 0.24 — —
Ki-67 LI
X20 vs o20% 3.50 (2.17–5.65) o0.001 2.69 (1.61–4.50) o0.001
Peritumoral vascular invasion
Present vs absent 1.75 (1.16–2.65) 0.008 2.27 (1.42–3.62) o0.001
Neoadjuvant response
No response vs complete/partial 1.49 (0.99–2.22) 0.054 1.07 (0.69–1.68)
b 0.76
Regimen
Anthracyclines and taxanes vs anthracyclines or others 1.20 (0.77–1.86) 0.43 — —
IBC¼inflammatory breast cancer; NIBC¼noninflammatory breast cancer.
aThe seven patients with complete pathological response were not considered, as the biological
variable at surgery was not available.
bEstimate relative to partial response vs no response.
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a recent meta-analysis on the prognostic role of
Ki-67 LI in more than 12000 patients with early breast cancer
(de Azambuja et al, 2007).
Moreover, our analyses show that the presence of PVI
significantly correlate with high risk of early recurrence. The
prognostic role of the extent of PVI in operable breast cancer was
recently reported (Colleoni et al, 2007). Therefore, the presence of
vascular invasion should be considered in the therapeutic
algorithm to properly select targeted adjuvant treatment.
Limited data are available on the relationship between HER2
overexpression and outcome in LABC. In two large studies
focusing on preoperative therapy DFS was significantly worse for
those patients whose tumours overexpressed HER2, as compared
with those with HER2-negative tumours (Gregory et al, 2000;
Guarneri et al, 2006). Results in LABC are conflicting and do not
support an independent prognostic role for HER2 status (Tulbah
et al, 2002), as observed in the current study. We reached the same
result about HER2 prognostic role also when we included in the
analysis patients who received trastuzumab therapy.
Inclusion of targeted anti-HER2 therapy in the primary systemic
treatment programme for selected patients with HER2-positive
LABC might improve treatment outcome for these patients. Results
from two randomised trials comparing primary chemotherapy
including taxanes and anthracyclines plus/minus trastuzumab
indicated that the clinical course of HER2-positive breast cancer
can be modified by the preoperative use of targeted therapies
(Buzdar et al, 2007; Gianni et al, 2007).
In conclusion, this study confirms the value of prognostic
parameters assessed at final surgery, including ER and PgR
expression, Ki-67 expression and presence of vascular invasion.
However, these results could be helpful to identify a subgroup of
patients with very high risk of early relapse for which we need
improved adjuvant therapy. Database analyses with longer follow-
up (especially for patients with endocrine responsive disease) or
prospective trials will be useful to confirm the value and
limitations of these factors in patients with LABC. Future adjuvant
treatments should anyhow consider tailored interventions to be
added to conventional combined preoperative therapy, because
these are likely to improve the clinical outcome of patients with
LABC, who otherwise will continue to have a dire prognosis. A
treatment for these cohorts of patients within the context of
clinical research programmes (i.e., prospectively defined tailored
treatments and long-term mandatory follow-up) should be viewed
as standard of care for a faster progress in the field.
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